If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Oric Pharmaceuticals Inc. (ORIC)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. At ORIC, their fully integrated discovery and development team is advancing a diverse pipeline of innovative therapies designed to counter resistance mechanisms in cancer by leveraging their expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Their lead product candidate, ORIC-101, builds upon a legacy of successful drug development by their founders in the field of nuclear hormone receptors and their efforts to elucidate the cause of resistance to the groundbreaking prostate cancer therapies that they had developed. ORIC-101 is a potent and selective small molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. In 2019, they initiated two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors, and they expect to report interim data from one of these trials in the first half of 2021 and from the other trial in the second half of 2021.
Jacob M. Chacko Dominic Piscitelli
Employees Founded
57 2014


Address: 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080, US

Telephone: (650) 388-5600

Web page:

IPO information

Expected Date 4/24/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $413.1
Revenues (MM) $0
Net Income (Loss) (MM) $-26.9


What do you think will happen with the ORIC share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 5
Shares Revised (MM) 7.5
Expected offer amount (MM) $120
Realized offer amount(MM) $120
J.P. Morgan/ Citigroup/ Jefferies/ Guggenheim Securities

Sector: Healthcare

Tweets about $ORIC

Tweets volume:

RT volume:


Google Trends Stats